Abivax (NASDAQ:ABVX) Price Target Raised to $145.00 at Morgan Stanley

Abivax (NASDAQ:ABVX) had its price objective hoisted by equities researchers at Morgan Stanley from $101.00 to $145.00 in a report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Morgan Stanley’s price objective points to a potential upside of 25.55% from the stock’s previous close.

ABVX has been the topic of several other research reports. JMP Securities boosted their price target on Abivax from $95.00 to $114.00 and gave the stock a “market outperform” rating in a research note on Thursday, September 25th. Truist Financial set a $140.00 target price on Abivax in a report on Monday, November 24th. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. BTIG Research lifted their price target on Abivax from $120.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $135.08.

Abivax Trading Down 8.7%

Shares of ABVX stock opened at $115.49 on Friday. The company has a market capitalization of $9.00 billion, a P/E ratio of -27.63 and a beta of 0.68. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $119.93 and its two-hundred day moving average is $83.80. Abivax has a twelve month low of $4.77 and a twelve month high of $148.83.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share (EPS) for the quarter. The company had revenue of ($4.92) million for the quarter. Equities analysts forecast that Abivax will post -2.83 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock valued at $32,000 after acquiring an additional 369 shares during the last quarter. First Horizon Corp bought a new position in shares of Abivax during the third quarter valued at approximately $36,000. Bank of America Corp DE raised its position in shares of Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new stake in Abivax in the third quarter worth $52,000. Finally, Cubist Systematic Strategies LLC boosted its holdings in shares of Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after acquiring an additional 2,595 shares during the period. 47.91% of the stock is owned by institutional investors and hedge funds.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.